<DOC>
	<DOCNO>NCT02957032</DOCNO>
	<brief_summary>Phase I , open label , non-randomized , multicenter , prospective dose escalation study F16IL2 combination low-dose cytarabine subject acute myeloid leukemia relapse allogeneic hematopoietic stem cell transplantation ( alloHSCT ) .</brief_summary>
	<brief_title>A Study Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein Combination With Very Low-dose Cytarabine Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation</brief_title>
	<detailed_description>Phase I , open label , non-randomized , multicenter , prospective dose escalation study F16IL2 combination low-dose cytarabine subject acute myeloid leukemia relapse allogeneic hematopoietic stem cell transplantation ( alloHSCT ) . The aim study determine recommend dose F16IL2 AML relapse alloHSCT investigate toxicity combination regimen . Patients enrol sequentially cohort treat different dose level F16IL2 fix dose cytarabine . All patient first receive initial run-in dose 30 Mio IU F16IL2 day 1 escalating dos F16IL2 day 1 , 8 , 15 22 . Patients treated cytarabine ( 5 mg twice daily s.c. 10 day ) . The following F16IL2 administration dose respective cohort ( day 8 , 15 22 ) . The RD define follow traditional 3+3 design . The dose escalation continue MTD find , least two patient among cohort three six patient experience dose limit toxicity ( DLT ) ( i.e. , &gt; 33 % patient DLT ) . The RD define dose level MTD level . If MTD find cohort 5 RD study consider equal cohort 5 dosage .</detailed_description>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>1 . Patients AML ( except APL ) relapse alloHSCT meeting follow criterion ( least one feature must present ) : bone marrow blast ≥ 5 % nucleated cell appearance blast peripheral blood extramedullary AML relapse . 2 . Age ≥18 year . 3 . ECOG ≤ 2 . 4 . Documented negative test HIVHBVHCV . For HBV serology : determination HBsAg , antiHBsAgAb antiHBCAgAb require . In patient serology document previous exposure HBV ( i.e. , antiHBs Ab history vaccination and/or antiHBc Ab ) , negative serum HBVDNA require . 5 . Negative serum pregnancy test female childbearing potential* within 14 day start treatment . 6 . Informed consent , personally sign date participate study . 7 . Willingness ability comply schedule visit , treatment plan , laboratory test study procedure . Women childbearing potential ( WOCBP ) must use , screen six month follow last study drug administration , highly effective contraception method , define `` Recommendations contraception pregnancy test clinical trial '' issue Head Medicine Agencies ' Clinical Trial Facilitation Group ( www.hma.eu/ctfg.html ) include , instance , progesterononly combine ( estrogen progesteroncontaining ) hormonal contraception associate inhibition ovulation , intrauterine device , intrauterine hormonereleasing system , bilateral tubal occlusion , vasectomise partner sexual abstinence . Pregnancy test repeat end treatment visit . Women childbearing potential define female experience menarche , postmenopausal ( 12 month menses without alternative medical cause ) permanently sterilise ( e.g. , tubal occlusion , hysterectomy , bilateral oophorectomy bilateral salpingectomy ) . 1 . Known central nervous system manifestation AML . 2 . Previous therapy ( chemotherapy , radiotherapy , investigational drug ) current AML relapse alloHSCT , unless previous treatment yield document progression disease except hydroxyurea control peripheral cell count 24h study medication . 3 . Active GvHD require systemic immunosuppression , unless control low dose steroid equivalent maximum 10 mg methylprednisolone per day . 4 . All acute toxic effect prior therapy return G≤1 accord CTCAE v4.03 ( exclude alopecia ) 5 . Chronically impaired renal function ( creatinine clearance &lt; 30 ml/min ) . 6 . Inadequate liver function ( ALT , AST , AP total bilirubin ≥ 3.0 x ULN ) , cause leukemic infiltration . 7 . Any severe concomitant condition make undesirable patient participate study could jeopardize compliance protocol . 8 . History within last year acute subacute coronary syndrome include myocardial infarction , unstable severe stable angina pectoris . 9 . Heart insufficiency ( &gt; Grade II , New York Heart Association ( NYHA ) criterion ) . 10 . Irreversible cardiac arrhythmia require permanent medication . 11 . LVEF &lt; 50 % 12 . Uncontrolled hypertension . 13 . Ischemic peripheral vascular disease ( Grade IIbIV ) . Severe diabetic retinopathy severe nonproliferative retinopathy proliferative retinopathy . 14 . Major trauma include surgery ( abdominal/cardiac/thoracic surgery ) within 4 week administration study treatment . 15 . Pregnancy breast feed . 16 . Requirement chronic administration corticosteroid . However , low dose corticosteroid ( maximum 10 mg methylprednisolone ( equivalent ) per day administer GVHD cancer symptom ( e.g. , pain , dyspnoea , lack appetite ) . 17 . Presence active uncontrolled infection severe concurrent disease , , opinion investigator , would place patient undue risk interfere study . 18 . Known active latent tuberculosis ( TB ) . 19 . Concurrent malignancy AML ( except basal cell squamous cell carcinoma skin carcinoma situ cervix breast ) unless patient diseasefree least 2 year . 20 . Concomitant treatment angiogenesis inhibitor drug proven antileukemic activity . 21 . Serious , nonhealing wound , ulcer bone fracture . 22 . Allergy study medication excipients study medication ( include drug fever rash cytarabine ) . 23 . Concurrent use anticancer treatment agent exception palliative radiation , e.g . myelosarcoma lesion blind efficacy judgement study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>